How a lack of leadership in HIV prevention is failing those at risk of infection in the UK (and beyond) In July 2012, the US Food and Drug Administration took a landmark decision when it approved the use of the antiviral Truvada for the prevention
It has now been 6 months since the PROUD and IPERGAY clinical studies investigating Pre-Exposure Prophylaxis (PrEP) for the prevention of HIV infection had to change course due to the success of the antiretrovirals (ARV) used in these trials to prevent HIV acquisition in HIV
In a recent BMJ Blog Dr Rupert Whitaker cast a critical eye on Pre-Exposure Prophylaxis (PrEP) for the prevention of HIV infection, questioning its role as a public health intervention. The piece is challenging and although it rightly emphasises the need for a carefully planned
In a surprising move, the World Health Organisation has come out in support of Pre-Exposure Prophylaxis (PrEP), recommending Men who have Sex with Men (MSM) to consider its use for HIV prevention alongside the use of condoms. It will be a huge challenge for countries
Absence of evidence is not evidence of absence. Does the PARTNER study signal the death of condoms or should we curb our enthusiasm, and carry on pretending we use them? The preliminary results of the PARTNER study were one of the most talked about data